<DOC>
	<DOCNO>NCT00031876</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial determine effectiveness combine capecitabine paclitaxel treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Capecitabine Paclitaxel Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) capecitabine combine paclitaxel patient metastatic adenocarcinoma breast . - Determine clinical efficacy dose immediately precede MTD identify phase I , term response rate , time treatment failure , time disease progression , overall survival , patient . - Determine toxicity regimen patient . - Determine well-tolerated drug combination patient . OUTLINE : This dose-escalation , multicenter study capecitabine . Patients receive oral capecitabine twice daily day 1-14 paclitaxel IV 1 hour day 1 , 8 , 15 . Treatment repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat dose level immediately precede MTD . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-24 patient accrued phase I 15-46 patient accrue phase II study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic adenocarcinoma breast Patients phase I : Evaluable disease Patients phase II : Bidimensionally measurable disease Bone metastases consider measurable No know clinically suspect CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 64 Sex : Not specify Menopausal status : Not specify Performance status : WHO 02 Life expectancy : At least 12 week Hematopoietic : WBC great 3,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2 time ULN ( 3 time ULN liver metastasis present ) Renal : Patients phase I : Creatinine clearance least 50 mL/min Patients phase I II : Creatinine great 1.5 time ULN Cardiovascular : No grade 2 great atrioventricular block Other : No cognitive impairment severe psychiatric disorder No great grade 2 preexist peripheral neuropathy No prior concurrent malignancy except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer Able tolerate steroid premedication PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : More 6 month since prior adjuvant chemotherapy At least 1 year since prior continuous infusion fluorouracil capecitabine At least 1 year since prior taxane administer every 3 week No prior taxane capecitabine administer weekly No 1 prior chemotherapy regimen metastatic locally advanced breast cancer No concurrent chemotherapy Endocrine therapy : Prior hormonal treatment metastatic breast cancer allow No concurrent continuous glucocorticosteroids No concurrent systemic endocrine treatment breast cancer Radiotherapy : No concurrent radiotherapy indicator lesion 30 % bone marrow Surgery : Not specify Other : No concurrent anticancer treatment No concurrent immunosuppressive drug Concurrent bisphosphonates allow indicator lesion nonbone Able tolerate steroid premedication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>